Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 99 peer-reviewed journal articles Updated
Cardiology

Chagas Cardiomyopathy: A Patient Guide

At a Glance

Chagas cardiomyopathy can develop years after Trypanosoma cruzi infection as inflammation scars the heart, weakening its pump and disturbing its rhythm. Regular heart checks help detect changes early so medicines or devices can protect heart function.

Chagas cardiomyopathy is a unique and often “silent” heart condition caused by the parasite Trypanosoma cruzi (T. cruzi). For most people, the infection begins decades before any heart issues appear, often during childhood or travel in rural parts of Latin America [1]. Because the initial illness is usually mild or unnoticed, the parasite can live quietly in the body for 20 to 30 years without causing a single symptom [2]. This long, stable period is known as the chronic indeterminate phase, and for more than half of those infected, the disease will never progress beyond this point [3]. (Note: The disease starts with an acute infection, followed by the chronic indeterminate phase, and in some, progresses to chronic determinate cardiac or digestive disease.)

When the disease does move into the chronic determinate phase with cardiac involvement, it affects the heart in a way that is different from typical heart disease caused by clogged arteries. The parasite and the body’s own immune response trigger a “slow burn” of chronic inflammation, which gradually replaces healthy muscle with stiff scar tissue, a process called fibrosis [4]. This scarring can weaken the heart’s pump, change its physical shape—sometimes creating a small thinning or ballooning at the tip called an apical aneurysm—and disrupt the electrical “wiring” that keeps the heart beating steadily [5][6]. These changes are what may lead to the symptoms of heart failure, irregular heartbeats (arrhythmias), and an increased risk of stroke [7][8].

Managing Chagas cardiomyopathy requires a shift in how we think about treatment. While antiparasitic medications can kill the parasite in the early stages of infection, they do not reliably reverse established advanced structural damage or improve major cardiac outcomes in patients with established cardiomyopathy [9]. Instead, the focus of care becomes protecting the heart’s function using standard heart failure medications and, when necessary, advanced devices like pacemakers or implantable defibrillators (ICDs) to manage rhythm issues [10][11]. Because the heart can change slowly over time, the most powerful tool you have is serial surveillance—regularly scheduled check-ups and imaging to catch any changes before they become emergencies [12].

It is completely normal to feel a sense of shock or confusion when diagnosed with a condition that was contracted so long ago. However, a diagnosis is not a guarantee of future illness; it is an opportunity to take control. With modern medical guidelines and consistent monitoring, many people with Chagas disease live full, active lives for decades. By staying connected to a knowledgeable care team, you ensure that you are receiving the right monitoring and the most effective heart-protective treatments available today [13].

In this guide

7 chapters

01

Understanding Chagas Disease and Its Phases

Learn how Chagas disease progresses through acute, silent, and chronic phases, including cardiomyopathy risk, heart tests, treatment, and family testing.

02

How Chagas Affects the Heart: Biology and Pathology

Learn how Chagas cardiomyopathy causes heart scarring, dilation, aneurysms, and rhythm problems, and how ECG, blood tests, and cardiac MRI assess damage.

03

Symptoms, Red Flags, and Warning Signs

Learn the symptoms and emergency warning signs of Chagas cardiomyopathy, including heart failure, arrhythmias, fainting, stroke, and severe shortness of breath

04

Getting the Right Tests: Diagnosis and Monitoring

Learn how Chagas disease is confirmed with two antibody tests and how EKG, echocardiogram, cardiac MRI, and Holter monitoring track heart changes over time.

05

Antiparasitic Medications: Benznidazole and Nifurtimox

Learn how benznidazole and nifurtimox treat Chagas disease, when they may help cardiomyopathy, key side effects, blood-test monitoring, and safety precautions.

06

Treating Chagas Heart Disease (Standard of Care)

Learn how Chagas cardiomyopathy is treated with heart-failure medicines, rhythm devices, anticoagulation, ablation, transplant care, and ongoing PCR monitoring.

07

Prognosis, Risk Scores, and Long-Term Surveillance

Learn how Chagas cardiomyopathy risk scores, cardiac MRI scarring, and regular EKGs help guide prognosis, arrhythmia monitoring, and long-term care decisions.

Common questions in this guide

What is Chagas cardiomyopathy, and what does it do to the heart?
Chagas cardiomyopathy is heart disease caused by long-term infection with the Trypanosoma cruzi parasite. Ongoing inflammation can replace healthy heart muscle with scar tissue, weaken pumping, change the heart’s shape, and disturb its rhythm.
Can heart problems from Chagas disease appear years after infection?
Yes. The initial infection may be mild or unnoticed, and the parasite can remain quiet for 20 to 30 years before heart problems appear. Many people remain in a chronic indeterminate phase and never develop heart or digestive disease.
Which tests are used to monitor Chagas cardiomyopathy?
Monitoring focuses on the heart’s electrical system and pumping function, using regular check-ups and scheduled imaging. Your care team will decide how often testing is needed based on your health, symptoms, and results over time.
How is Chagas cardiomyopathy treated?
Antiparasitic medicines can kill the parasite during earlier stages of infection, but they do not reliably reverse advanced structural heart damage. Established cardiomyopathy is managed with standard heart failure medicines and, when needed, pacemakers or implantable defibrillators for rhythm problems.
Does a Chagas diagnosis mean I will develop serious heart disease?
No. More than half of people with Chagas infection remain in the chronic indeterminate phase and never develop cardiac or digestive disease. Regular monitoring and heart-protective treatment can help manage changes, and many people live full, active lives for decades.
Should I see a cardiologist or an infectious disease specialist for Chagas cardiomyopathy?
Both specialists may be helpful. A cardiologist evaluates heart rhythm and pumping function, while an infectious disease specialist addresses the parasite and infection history; they can coordinate your care.
Should my family members be tested for Trypanosoma cruzi?
Ask your care team whether family members need testing for Trypanosoma cruzi. The recommendation depends on their possible exposure and personal medical history, so an infectious disease specialist can guide the evaluation.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Given that I feel healthy now, what are the most important baseline tests I should have to check my heart's health?
  2. 2.How often will we need to monitor my heart's electrical system and pumping function?
  3. 3.Who should be the 'lead' on my care team—a cardiologist, an infectious disease specialist, or both?
  4. 4.What are the specific signs that my condition might be moving from the indeterminate phase to the determinate phase?
  5. 5.Are my family members at risk, and do they need to be tested for the T. cruzi parasite?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (13)
  1. 1

    Low risk for locally acquired Chagas disease in California: A review of human cases and triatomine submissions, 2013-2023.

    Lund AJ, Metzger ME, Kramer VL, Kjemtrup AM

    PLoS neglected tropical diseases 2025; (19(4)):e0013036 doi:10.1371/journal.pntd.0013036.

    PMID: 40258046
  2. 2

    American Trypanosomiasis (Chagas Disease).

    Echeverria LE, Morillo CA

    Infectious disease clinics of North America 2019; (33(1)):119-134 doi:10.1016/j.idc.2018.10.015.

    PMID: 30712757
  3. 3

    The Oxidative Stress and Chronic Inflammatory Process in Chagas Disease: Role of Exosomes and Contributing Genetic Factors.

    Maldonado E, Rojas DA, Urbina F, Solari A

    Oxidative medicine and cellular longevity 2021; (2021()):4993452 doi:10.1155/2021/4993452.

    PMID: 34976301
  4. 4

    Putting Infection Dynamics at the Heart of Chagas Disease.

    Lewis MD, Kelly JM

    Trends in parasitology 2016; (32(11)):899-911 doi:10.1016/j.pt.2016.08.009.

    PMID: 27612651
  5. 5

    Pathology of Chronic Chagas Cardiomyopathy in the United States:  A Detailed Review of 13 Cardiectomy Cases.

    Kransdorf EP, Fishbein MC, Czer LS, et al.

    American journal of clinical pathology 2016; (146(2)):191-8 doi:10.1093/ajcp/aqw098.

    PMID: 27425387
  6. 6

    Prevalence of Chagas heart disease in dilated cardiomyopathy.

    González-Zambrano H, Amaya-Tapia G, Franco-Ramos MC, López León-Murguía OJ

    Archivos de cardiologia de Mexico 2020; (91(1)):50-57 doi:10.24875/ACM.20000042.

    PMID: 33079075
  7. 7

    Sudden Cardiac Death Risk Stratification and Prevention in Chagas Disease: A Non-systematic Review of the Literature.

    Keegan R, Yeung C, Baranchuk A

    Arrhythmia & electrophysiology review 2020; (9(4)):175-181 doi:10.15420/aer.2020.27.

    PMID: 33437484
  8. 8

    Prevalence and risk factors of embolic cerebrovascular events associated with Chagas heart disease.

    Nunes MC, Kreuser LJ, Ribeiro AL, et al.

    Global heart 2015; (10(3)):151-7.

    PMID: 26407510
  9. 9

    Randomized Trial of Benznidazole for Chronic Chagas' Cardiomyopathy.

    Morillo CA, Marin-Neto JA, Avezum A, et al.

    The New England journal of medicine 2015; (373(14)):1295-306 doi:10.1056/NEJMoa1507574.

    PMID: 26323937
  10. 10

    Adherence to Guideline-Directed Medical Therapy Target in patients with heart failure and reduced ejection fraction: a cross-sectional study.

    Costa FF, Chagas AKR, Santos ACML, et al.

    Sao Paulo medical journal = Revista paulista de medicina 2025; (143(3)):e2023315 doi:10.1590/1516-3180.2023.0315.R2.13082024.

    PMID: 40332281
  11. 11

    Implantable cardioverter-defibrillator in Chagas heart disease: A systematic review and meta-analysis of observational studies.

    Carmo AAL, de Sousa MR, Agudelo JF, et al.

    International journal of cardiology 2018; (267()):88-93 doi:10.1016/j.ijcard.2018.05.091.

    PMID: 29871807
  12. 12

    Multimodality imaging evaluation of Chagas disease: an expert consensus of Brazilian Cardiovascular Imaging Department (DIC) and the European Association of Cardiovascular Imaging (EACVI).

    Nunes MCP, Badano LP, Marin-Neto JA, et al.

    European heart journal. Cardiovascular Imaging 2018; (19(4)):459-460n doi:10.1093/ehjci/jex154.

    PMID: 29029074
  13. 13

    Risk of Chronic Cardiomyopathy Among Patients With the Acute Phase or Indeterminate Form of Chagas Disease: A Systematic Review and Meta-analysis.

    Chadalawada S, Sillau S, Archuleta S, et al.

    JAMA network open 2020; (3(8)):e2015072 doi:10.1001/jamanetworkopen.2020.15072.

    PMID: 32865573

This page provides general information about Chagas cardiomyopathy, heart monitoring, and treatment options; it does not replace medical advice. Ask a cardiologist or infectious disease specialist how the information applies to you.

Get notified when new evidence is published on Chagas cardiomyopathy.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.